

Appl. No. 10/606,632  
Reply to Office Action of January 25, 2006

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**Claims 1-5 (Canceled).**

**6. (Currently Amended)** A pharmaceutical composition comprising a diuretic and an insulin sensitizer in ratio of amount by weight of 1:200 to 200:1, wherein said insulin sensitizer is 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a pharmacologically acceptable salt thereof; and  
~~A pharmaceutical composition according to Claim 4, wherein said diuretic is amiloride.~~

**Claims 7-21 (Canceled).**

Appl. No. 10/606,632  
Reply to Office Action of January 25, 2006


**22. (New)** A pharmaceutical composition comprising a diuretic and an insulin sensitizer in a ratio of amounts by weight of 1:200 to 200:1, wherein

said diuretic is amiloride; and


said insulin sensitizer comprises one or more compounds selected from the group consisting of troglitazone, pioglitazone, rosiglitazone, JTT-501, MCC-555, GI-262570, YM-440, KRP-297, T-174, NC-2100, BMS-298585, AZ-242 and NN-622 represented by the formula below

Appl. No. 10/606,632


Reply to Office Action of January 25, 2006




Pioglitazone.




Rosiglitazone




JTT-501




MCC-555



GI-262570




YM-440




KRP-297


Appl. No. 10/606,632  
Reply to Office Action of January 25, 2006




T-174




NC-2100



BMS-298585



AZ-242



NN-622

Appl. No. 10/606,632  
Reply to Office Action of January 25, 2006

5-[4-(6-Methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a pharmacologically acceptable salt thereof.

**23. (New)** The pharmaceutical composition of claim 22, wherein said insulin sensitizer is troglitazone.

**24. (New)** The pharmaceutical composition of claim 22, wherein said insulin sensitizer is pioglitazone.

**25. (New)** The pharmaceutical composition of claim 22, wherein said insulin sensitizer is rosiglitazone.

**26. (New)** The pharmaceutical composition of claim 22, wherein said insulin sensitizer is JTT-501.

**27. (New)** The pharmaceutical composition of claim 22, wherein said insulin sensitizer is MCC-555.

**28. (New)** The pharmaceutical composition of claim 22, wherein said insulin sensitizer is GI-262570.

Appl. No. 10/606,632  
Reply to Office Action of January 25, 2006

29. (New) The pharmaceutical composition of claim 22,  
wherein said insulin sensitizer is YM-440.

30. (New) The pharmaceutical composition of claim 22,  
wherein said insulin sensitizer is KRP-297.

31. (New) The pharmaceutical composition of claim 22,  
wherein said insulin sensitizer is T-174.

32. (New) The pharmaceutical composition of claim 22,  
wherein said insulin sensitizer is NC-2100.

33. (New) The pharmaceutical composition of claim 22,  
wherein said insulin sensitizer is BMS-298585.

34. (New) The pharmaceutical composition of claim 22,  
wherein said insulin sensitizer is AZ-242.

35. (New) The pharmaceutical composition of claim 22,  
wherein said insulin sensitizer is NN-622.